Quick Answer
Magnesium Threonate Memory Randomized Trial has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: Results Compared to the placebo, Magtein ® was associated with greater improvements in overall cognitive performance as measured by the NIH Total Cognition Composite ( p = 0.043), with larger treatment effects on working and episodic memory.
Key Takeaways
- 01Results Compared to the placebo, Magtein ® was associated with greater improvements in overall cognitive performance as measured by the NIH Total Cognition Composite ( p = 0.043), with larger treatment effects on working and episodic memory. [Lopresti AL (2026)]
- 02Based on data from the sleep tracking ring, there were no group differences in sleep outcomes, although there was a greater reduction in HR ( p = 0.030) and an increase in HRV ( p = 0.036), a physiological marker of stress reduction and improved autonomic balance. [Lopresti AL (2026)]
- 03Conclusion The results from this study suggest Magtein ® supplementation for 6 weeks improves overall cognition, cognitive age, working memory, reaction time, HR, HRV, and some subjective, but not objective measures of sleep in healthy adults with self-reported dissatisfied sleep. [Lopresti AL (2026)]
- 04The purpose of this two-arm, 6-week, parallel-group, randomised, double-blind, placebo-controlled trial was to examine the effects of magnesium L-threonate (Magtein ® ) supplementation on cognitive performance, cognitive age, sleep quality, and selected physiological indicators in adults. [Lopresti AL (2026)]
The current Migaku evidence database contains 2 reusable source documents for Magnesium Threonate Memory Randomized Trial. This answer focuses on strength of evidence and what the studies can or cannot prove.
- Results Compared to the placebo, Magtein ® was associated with greater improvements in overall cognitive performance as measured by the NIH Total Cognition Composite ( p = 0.043), with larger treatment effects on working and episodic memory. [Lopresti AL (2026); evidence level 2]
- Based on data from the sleep tracking ring, there were no group differences in sleep outcomes, although there was a greater reduction in HR ( p = 0.030) and an increase in HRV ( p = 0.036), a physiological marker of stress reduction and improved autonomic balance. [Lopresti AL (2026); evidence level 2]
- Conclusion The results from this study suggest Magtein ® supplementation for 6 weeks improves overall cognition, cognitive age, working memory, reaction time, HR, HRV, and some subjective, but not objective measures of sleep in healthy adults with self-reported dissatisfied sleep. [Lopresti AL (2026); evidence level 2]
- The purpose of this two-arm, 6-week, parallel-group, randomised, double-blind, placebo-controlled trial was to examine the effects of magnesium L-threonate (Magtein ® ) supplementation on cognitive performance, cognitive age, sleep quality, and selected physiological indicators in adults. [Lopresti AL (2026); evidence level 2]
- 8 In particular, statins may indirectly affect neurodegenerative trajectories by improving cerebrovascular function and reducing vascular risk factors, which are increasingly appreciated as contributors to cognitive decline and mixed dementia phenotypes []. [Chiatto Luigi Maria (2026); evidence level 3]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources
- The effects of magnesium L-threonate (Magtein<sup>®</sup>) on cognitive performance and sleep quality in adults: a randomised, double-blind, placebo-controlled trial.
- The Use of Statins in Parkinson's and Alzheimer's Disease: A 2021–2025 State‐of‐the‐Art Review of Clinical and Preclinical Evidence